

## News Release

December 21, 2021  
Carna Biosciences, Inc.

### **Carna Announces to Extend the Agreement with Sumitomo Dainippon Pharma on Joint Research, Development, and Commercialization of Kinase Inhibitors**

Carna Biosciences, Inc. (Head Office: Kobe, Japan, President and CEO: Kohichiro Yoshino) announces that Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan, Representative Director, President and CEO: Hiroshi Nomura) and Carna have agreed a three-year extension to the joint research collaboration for discovering novel kinase inhibitors for psychiatric and neurological disorders. The two companies have entered into the agreement on March 27, 2018 on the joint research, as well as on the subsequent development and commercialization of such therapeutic agent(s) (hereinafter referred to as the "Agreement").

Under the Agreement, the two companies have conducted the joint research to discover novel kinase inhibitors for psychiatric and neurological disorders by combining accumulated Carna's know-how on kinase inhibitor discovery with Sumitomo Dainippon Pharma's know-how on drug discovery research in the area of neuroscience. Over the last four years, the Sumitomo Dainippon-Carna collaboration has generated promising data and new intellectual properties for new drug candidates for treating psychiatric and neurological disorders. The joint research has been extended until March 27, 2025 and Sumitomo Dainippon Pharma and Carna will continue the research to deliver innovative drugs in targeting psychiatry and neurology, where unmet medical needs are high.

Sumitomo Dainippon Pharma retains exclusive worldwide rights to the clinical development and marketing of any kinase inhibitors that may be discovered through the joint research and that Sumitomo Dainippon Pharma decides to commercialize (hereinafter referred to as the "Agent(s)") for all therapeutic areas except oncology. Pursuant to the Agreement, Sumitomo Dainippon Pharma will provide up to 80 million yen to Carna as an upfront payment and milestone payments in each research phase, of which Carna received an upfront payment of 50 million yen in the second quarter of the fiscal year ending December 2018.

When Sumitomo Dainippon Pharma decides the transition to clinical development and marketing of the Agent(s), Sumitomo Dainippon Pharma will also provide up to approximately 10.6 billion yen in total to Carna with development milestone payments in each development phase and milestone payments on sales that will be calculated on the basis of sales target achievement. In addition, Sumitomo Dainippon Pharma will pay a specified amount of royalties to Carna in accordance with the sales amount of the Agent(s) following commercial launch.

Contact:  
Corporate Planning  
Carna Biosciences, Inc.  
TEL: +81-78-302-7075  
<https://www.carnabio.com/english/>